Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769225 | 0.78 | — | — | |
| SCHEMBL5324357 | 0.76 | ESR1 (0.43) | ALDH1A1RAB9ANPC1CYP3A4ALOX15 | |
| SCHEMBL511496 | 0.76 | LMNA (0.41) | ALDH1A1RAB9ANPC1CYP2C19DDAH1 | |
| SCHEMBL512928 | 0.76 | NOTUM (0.42) | ALDH1A1RAB9ANPC1CYP2A6HPGD | |
| SCHEMBL21295791 | 0.76 | MAPT (0.43) | ALDH1A1RAB9ANPC1CYP3A4CYP2D6 | |
| SCHEMBL3608419 | 0.76 | GAA (0.41) | ALDH1A1RAB9ANPC1CYP2A6TSHR | |
| SCHEMBL2462291 | 0.74 | CYP2A6 (0.52) | ALDH1A1RAB9ANPC1CYP3A4CYP2E1 | |
| SCHEMBL5474340 | 0.74 | NR4A1 (0.44) | NOTUMGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL5327871 | 0.72 | KIF11 (0.43) | ALDH1A1CYP3A4CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL314750 | 0.72 | EGFR (0.47) | ALDH1A1RAB9ANPC1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| WO-2000061134-A9 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2004-04-22 | — | — | WO | claimed |
| US-6716878-B1 | BACTERICIDE, ANTIPROTOZOAL; VANCOMYCIN RESISTANT ENTEROCOCCI AND BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA, METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; HYDROXAMIC ACID AND N-FORMYL SUBTITUTED ALKYLAMIDES | VERNALIS (OXFORD) LIMITED (GB) | 2004-04-06 | — | — | US | claimed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| JP-2002541197-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | claimed |
| EP-1169031-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-01-09 | — | — | EP | claimed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | ALDH1A1 1424/4885RAB9A 3592/4885NPC1 2336/4885 |
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | ALDH1A1 603/4885RAB9A 4348/4885NPC1 2949/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | ALDH1A1 1424/4885RAB9A 3592/4885NPC1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.